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ACKGROUND: Asymmetric dimethylarginine 
(ADMA) is a competitive inhibitor of nitric 
oxide synthase (NOS). ADMA reduces NO 
synthesis when its concentration elevates. ADMA 
is a novel risk factor for cardiovascular disease. 
Plasma ADMA accumulates in patients with end-
stage renal disease, due to reduced renal clearance. 
Hyperhomocysteinemia is often found in patients with 
chronic kidney disease (CKD). Homocysteine may cause 
ADMA to accumulate; however, the mechanism by 
which ADMA level elevates in hyperhomocysteinemia 
is still unclear.  Objective of this study was to analyze 
the concentrations of homocysteine and ADMA and 
to assess the correlation between homocysteine and 
ADMA concentrations with the severity of chronic 
kidney disease.  
METHODS: This was a cross-sectional study 
on 75 patients with CKD, comprising men and 
women aged 40-70 years. Assessments were done 
on the concentrations of creatinine, homocysteine, 
ADMA, fasting blood glucose, cholesterol HDL and 
triglyceride. 
RESULTS: In later stage of CKD there was signiﬁcantly 
higher tHcy concentration as compared with the earlier 
stage of CKD (p=0.0000). In CKD stage 2 to 4 there was 
a tendency for ADMA concentration to increase to a 
signiﬁcant average (p=0.210), but ADMA concentration 
was lower at stage 5. There was increased ADMA 
along with increased tHcy concentration of around 
20µ mol/L, and this then decreased. The inverse 
correlation between tHcy and ADMA concentrations 
started to appear in CKD stage 4, but this correlation 
was statistically insigniﬁcant (r2 = 0.19; p=0.499).
CONCLUSIONS: This study showed there was 
a correlation between homocysteine and ADMA 
concentrations in patients with CKD stage 2 to 5, 
although statistically not signiﬁcant.
KEYWORDS: Asymetric Dimethylarginine, 
Homocysteine, Chronic Kidney Disease.
Kidney failure (stage 5 Chronic Kidney Disease = 
CKD) is an important health problem, considering 
its increasingly high incidence and prevalence 
besides the very expensive medication, including 
renal replacement therapy, that the patients with 
kidney failure must undergo. Globally, in 1966 there 
were approximately one million patients with CKD 
underwent renal replacement therapy (hemodialysis, 
peritoneal dialysis, or kidney transplantation); and 
this number will increase to 2 million in 2010 (1).
Cardiovascular disease is often seen in patients 
with CKD either at the pre-dialysis phase or mainly 
at the dialysis phase. Cardiovascular disease is the 
main cause of death in patients with CKD, with its 
estimated incidence 10 to 100 times greater than that 
in the population without CKD (2). 
In addition to the conventional/traditional 
factors of cardiovascular disease such as smoking, 
diabetes, hypertension, dyslipidemia, and obesity at 
all stages of kidney disease, there are non-traditional 
risk factors or uremia-related risk factors such as 
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increased homosysteine, C-reactive protein (CRP), 
asymmetric dimethylarginine (ADMA) concentration, 
occurrence of microinﬂammation, proteinuria, and 
increased oxidative stress, all of which contribute to 
the progression of these cardiovascular disease risks 
(2,3). 
Clinical evidences have indicated that not all 
patients with CKD in the early stage progressed into 
renal failure, and that the percentage of early stage CKD 
that progressed to renal failure varied among patients. 
It was suggested that several factors contributed to the 
progression of early stage chronic kidney disease into 
kidney failure, and intervention on the risk factors if 
done at the early stage could slow down progression; 
in fact in several conditions it could even totally stop 
progression into kidney failure (1). 
Homocysteine is an amino acid-containing 
sulphydril group that originates from the essential 
amino acid methionin that comes in great abundance 
from vegetable fat. The metabolic pathway that 
changes methionine to homosysteine is very important 
for many biomolecules to maintain their normal 
functions, including DNA, proteins, phospholipids and 
neurotransmitters (4). Homocysteine concentration 
elevates along with worsening of the kidney function 
(2,5). In several studies homocysteine was proposed as 
a cardiovascular risk factor. 
Asymmetric dimethylarginine (ADMA) is an 
arginine form modiﬁed post-translationally from all 
cells during protein modiﬁcation process. ADMA is 
a guanidine compound synthesized in endothelial 
cells. ADMA concentration elevates along with the 
worsening of the kidney function (6). ADMA is a 
competitive inhibitor from endothelial nitric oxide 
synthase (eNOS). eNOS is an enzyme that modiﬁes 
L-arginine to become nitric oxide (NO). NO plays 
an important role in maintaining normal endothelial 
functions as vasodilator, anti thrombosis, and anti 
proliferation. Elevated ADMA can diminish NO 
availability, thus ADMA is suggested to be an 
important cardiovascular risk factor (7). 
Several studies using experimental animals 
and clinical studies have indicated there was a close 
correlation between total plasma homocycsteine and 
plasma ADMA concentration (8). 
Homocysteine is an important part of methylation 
process. S-adenosylomethionine (SAM) is a methyl 
donor that enables arginine methylation and produce 
S-adenosylhomocysteine (SAH); in turn it can be 
modiﬁed into homocysteine. Results of several studies 
suggested that ADMA produced by human endothelial 
cells was upregulated in the presence of methionine 
or homocysteine and inhibited by metyltransferase-
inhibiting SAH. 
In situations where homocysteine level increases, 
the concentration of intracellular SAH can elevate. 
Since SAH is a potent inhibitor to transmethylation 
reactions, its accumulation can cause macromolecules 
hypomethylation. According to this mechanism, DNA 
hypomethylation occurs in hyperhomocysteinemic 
patients with end-stage kidney disease. In the later 
condition, production of ADMA by endothelial cells is 
inhibited through incubation by SAH (9). 
Two isoforms of dimethylarginine 
dimethylhidrolase (DDAH) have been identiﬁed: 
DDAH-I is mostly found in the neural tissues, whereas 
DDAH-II dominates in peripheral and vascular 
tissues. DDAH is an intracellular protein whose role in 
several disease conditions has been studied. Because 
its enzymatic role is to selectively hydrolyze ADMA 
to form L-citrulline and dymetilamine, reduced 
enzymatic DDAH expression or activity can elevate 
the concentration of ADMA (9).    
Homocysteine can inhibit DDAH activity, 
probably because of its interaction with important 
cysteine residue in active enzyme site. Several studies 
have suggested the possibility that every existing 
correlation between homocysteine and cardiovascular 
risk might possibly indicate a correlation reﬂection 
between ADMA and cardiovascular risk (6). 
Methods
STUDY DESIGN AND PARTICIPANTS
This study used a Cross Sectional Study design. The 
study population comprised patients examined at the 
Kidney Polyclinic of Wahidin Hospital, Makasar. The 
study subjects were selected from the study population 
who qualiﬁed as samples according to the inclusion 
and exclusion criteria. Inclusion criteria for samples 
are : (1) Suffering chronic kidney disease according 
to the criteria of Kidney Disease Quality Outcome 
Initiative (K/DOQI), (2) Suffering diabetes mellitus 
according to PERKENI criteria, (3) Not undertaking 
hemodyalisis, (4) Not undertaking medication with 
Statin derivates, and Exclusion criteria for sample is 
subjects who rejected to participate in the study.
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DATA COLLECTION  
The examinations w ere conducted a t the K idney 
Polyclinic o f Wahidin Hospital, Makasar, P rodia 
Clinical Laboratory Branch o f Makassar, and P rodia 
Clinical Laboratory Kramat-Jakarta, f rom November 
2006 to March 2007. Sampling was done by consecutive 
sampling method, i.e. selecting samples from patients 
visiting the Kidney Polyclinic o f Wahidin H ospital, 
Makasar t hroughout the s tudy period who met t he 
inclusion criteria, u p to the calculated number of 
sample size was reached. 
The examinations done included the followings:
a. Interview, to gather i nformation on personal 
characteristics and general aspects of the s tudy 
subjects such as: age, sex, disease history including 
familial diseases, smoking, type of medication 
undertaken, etc, using prepared questionnaires. 
b. Physical examinations, t o obtain t he information 
on blood pressure, temperature, weight, and other 
relevant physical features. 
c. Laboratory examinations, t o obtain data of 
creatinine, homocysteine, ADMA, and f asting 
glucose levels.    
Data analysis was done using SPSS software for 
windows version 11.5 and Microsoft Excel 2000. One-
Sample Test was used t o assess i f data had normal 
distribution at a  conﬁdence limit p  =  0 .05. Mean 
differential test of two independent groups was done 
using t test  o r Mann-Whitney test. Mean differential 
test o f more than t wo g roups was done by Kruskal-
Wallis H test. Linear correlation was assessed by the 
Pearson or Spearman. Non-linear correlation test was 
performed t o assess correlation o f two data groups: 
quadratically, logaritmatically or inversely.  
Table 1. Criteria for Kidney Dysfunction
m 37.1/nim/Lm( GFLnoitpircseDegatS 2 LPT)
 
   09 > ro lamron htiw tcefed yendiK 1
 i ncreased kidney function
2 Kidney defect with mild decrease of 60–89   
 k idney function
3 Moderate decrease of kidney function 30–59
4 Severe decrease of kidney function 15–29
   )sisylaid ro( 51 < eruliaf yendiK 5
Results
Based on data of the interviews, physical examinations, 
biochemical examinations, the individual characteristics 
of the study subjects could be summarized as shown 
in Table 1.
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Note: p = probability
Table 4. ADMA concentrations (  mol/L) based on CKD levels
CKD level n Mean Standard  Minimum Maximum p
   deviation 
CKD stage 2 31 0.7001 0.19865 0.19 1.12
CKD stage 3 24 0.7521 0.24705 0.09 1.23
CKD stage 4 10 0.8692 0.20770 0.60 1.25
CKD stage 5 11 0.6596 0.38416 0.10 1.09 0.210
Correlation between tHcy and ADMA concentration by 
linear regression showed that there was no signiﬁcant 
correlation between ADMA concentration with tHcy 
with r2 = 0.19 and p = 0.499. 
Correlation analysis between ADMA and tHcy 
concentration at each CKD level indicated the presence 
of positive correlation among them at CKD stage 2 
and 3, however, inverse correlation between tHcy and 
ADMA concentration started to occur at stage 4 
In this study there were 20 DM patients and 
55 non-DM patients. Higher tHcy and ADMA 
concentration means were observed but they were no 
signiﬁcant difference between non-DM patients and 
DM patients.
p MD MD noN 
tHcy 13.602 ± 7.6987 11.500 ± 3.6878 0.246
ADMA 0.7525 ± 0.2492 0.6869 ± 0.26103 0.322
Tabel 5. Mean of homocysteine and ADMA concentration in DM and in non-DM patients
    
If tHcy concentration   12 mol/L was categorized 
as abnormal and this concentration represented cutoff 
value for PKV risk, by logistic binary test on the 
 noisnetrepyh ,MD fo ecneserp ,xes ,ega ,GFL selbairav
and dyslipidemia, then it would show that LFG 
(estimation) is the most essential variable (p=0.000) of 
the elevation of homocysteine concentration.
If ADMA concentration >0.75  mol/L was 
categorized as abnormal, this study showed that 33 
 noitartnecnoc AMDA evah dluow )%44( stcebus
 57.0 > evah dluow  )%5( stcebus 24 dna L/lom 57.0
mol/L. If ADMA concentration > 0.75  mol/L was the 
cutoff value for PKV, with logistic binary test on the 
variables GF  (estimation), age, sex, presence of DM, 
hypertension, and dyslipidemia, then it would show 
that sex and age were the statistically most signiﬁcant 
variables (p 0.004 and 0.012) of the elevation of ADMA 
concentration. 
y sex variable, there were 32 female sub ects 
(42.7%) and 43 male sub ects (57.3%) involved in this 
study. f the 32 female sub ects, 24 sub ects (75%) 
were with ADMA concentration > 0.75 mol/L (mean 
of age 55 years) and  sub ects (25%) with ADMA 
concentration   0.75  mol/L (mean of age  years). 
Meanwhile, of 43 male sub ects there were 1  sub ects 
(41.9%) with ADMA concentration > 0.75  mol/L (mean 
of age 52 years) and 25 sub ects (5 .1%) with ADMA 
concentration  0.75  mol/L (mean of age 5  years). 
esult of the t test showed there was no 
statistically signiﬁcant difference between the age 
mean of the female study sub ects with elevated ADMA 
concentration and that of the female study sub ects 
with non-elevated ADMA (p=0.092). In contrast, it was 
found that the mean of age of the male study sub ects 
with elevated ADMA concentration was signiﬁcantly 
different from that of the male sub ects having non-
elevated ADMA concentration (p=0.011). 
Discussion
able 3 indicated that in CKD patients there was a 
difference of the mean of tHcy concentration according 
to CKD severity levels, in which at later CKD stage, the 
mean of tHcy concentration was signiﬁcantly higher 
(p=0.000) than at earlier stage. 
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CKD is almost often correlated with 
hyperhomosysteinemia. Plasma homocysteine 
concentration is closely correlated with decrease of LFG 
concentration in which elevated tHcy concentration 
starts to occur at LFG < 60 ml/minute/1.73 m2. 
Prevalence of hyperhomocysteinemia in CKD is about 
85-100% according to CKD severity. The relationship 
mechanism of LFG with elevated plasma homocysteine 
concentration is not yet fully understood (10). 
In general, patients with kidney disease have 
normal methionine, betaine and vitamin B plasma 
level, increased AdotMet, Ado Hcy, cysteine and 
sulfate, and decreased serine concentration. It seems 
that in patients with kidney disease, the plasma 
homocysteine concentration has close correlation with 
plasma folate, AdoHcy and cysteine concentrations. 
The mechanism that can explain this phenomenon 
may be related with the inhibited homocysteine re-
methylation and impaired cysteine excretion  
The mechanism of protein re-methylation 
inhibition is supported by results of studies that have 
indicated that successful treatment regimen could 
lower its concentration in CKD. 
Impairment of cysteine excretion was reported by 
Suliman et al who suggested that in CKD inhibition 
of cysteinesulphunic acid decarboxylation, which is 
synthesis of cysteine and taurine alteration, caused 
elevation of hyperhomocysteine concentration. 
A study using stable isotope method to observe 
systemic homocysteine metabolism in patients with 
kidney failure and in healthy individuals found that 
remethylation ﬂux and total transmethylation were 
reduced in CKD patients. 
Two mechanisms may explain the increase of 
plasma homocysteine concentration and reduced 
ﬂux through methylation cycle in patients with 
kidney failure: 1) the presence of primary defect in 
homocysteine metabolism can result in homocysteine 
transulfuration impairment. On the other side, higher 
homocysteine concentration results in the slower 
methylation cycle by inhibiting transmethylation.; 
2) the occurrence of pimary defect can result in 
homocysteine transmethylation. Of this study, the 
hypothesis was that an unknown substance - able to 
ﬁltrate the glomerular sites- regulated homocysteine 
excretion through re-methylation or transulfuration.        
Table 4 indicated that in CKD stage 2 to 4 there 
was a tendency of insigniﬁcant elevation of the mean 
ADMA concentration (p=0.210). In CKD stage 5, there 
was lower ADMA concentration mean. 
ADMA is arginine form modiﬁed post-
translationally and synthesized by all cells during 
protein modiﬁcation process. ADMA is well-known as 
an independent predictor for cardiovascular morbidity 
and mortality and its status as cardiovascular risk 
factor has been generally accepted. NOS competitive 
inhibition most likely becomes ADMA effect 
mechanism on the cardiovascular system, though 
nitric oxide (NO)-related mechanisms shouldn’t be 
ignored. Only free ADMA, and not its bind protein, 
is able to inhibit NOS. Since NOS is an intracellular 
cell, concentration of free intracellular ADMA - not its 
plasma concentration - is associated in NOS inhibition. 
Free ADMA is formed exclusively through sequence 
of protein arginine residue methylation, followed by 
the protein proteolysis. There are two paths for ADMA 
clearance from cells. First, ADMA is degadraded 
enzymatically by DDAH to become citrulline and 
dimethylamine. Second, the path enhances ADMA 
transport from the cell to plasma through cationic 
acid transporters (CAT) in its plasma membrane. In 
addition, clearance from plasma compartment occurred 
through two routes: renal excretion and uptake by 
cell through CAT. Thus, CAT activity is involved in 
cellular release and ADMA uptake, and consequently, 
it plays important role in intracellular and inter-organ 
ADMA transportation. Both the kidney and liver seem 
to become important organs in ADMA clearance from 
plasma (9). 
The actual mechanism that results in ADMA 
accumulation in CKD patients is not yet fully 
understood. One known mechanism is that reduced 
ADMA excretion has a linear relationship with 
reduced kidney function. In CKD, plasma ADMA 
concentration is increased to 1 - 3  mol/L (11). 
A study suggested that in intravenous 
dimethylarginine supplementation, 66% of ﬁltrated 
SDMA would be reabsorbed, whereas only 5% of 
ﬁltrated ADMA would be reabsorbed. 
Result of a study on molecular mechanism of 
increased ADMA plasma concentration in CKD using 
model mice with progressive CKD suggested that 
disregulation on enzyme PRMT and DDAH occurred 
as a result of oxidative stress. This mechanism was 
supported by the evidences that : (1) gene expression 
PRMT type I is increased by oxidized LDL in endothelial 
cells (EC) cultured by a redox-regulated mechanism; 
(2) DDAH activities in EC and smooth muscles is 
decreased in high-glucose condition, which is blocked 
by an antioxidant, superoxide dismutase. It is known 
that oxidative stress is increased in CKD patients. In 
addition to oxidative stress, there are uremic toxic 
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like homocysteine and AGE products that decrease 
DDAH activity, which can cause disregulation of these 
enzyme. 
The factors that have caused the insigniﬁcance 
of the ADMA elevation in our present study may 
possibly relate to the not-observed random variables 
like smoking, duration of hypertension, type of 
hypertension medication, and duration of diabetes 
and anti-diabetes therapy.
In this study the mean value of ADMA 
concentration was found to be lower in the earlier 
stages of CKD than in stage 5. This will be explained 
in more detail in the next analysis of correlation of 
homocysteine and ADMA. 
Result of the correlation analysis between tHcy 
and ADMA using linear regression showed that the 
data distribution among two variables indicated 
quadratic model, in which there was ADMA elevation 
simultaneously with tHcy up to the concentration of 
tHcy of about 20 mol/L, then decreased. The analysis 
found no signiﬁcant correlation between ADMA and 
tHcy concentration. 
Correlation analysis between ADMA and tHcy 
concentration in each CKD severity level indicated 
positive correlation in CKD stage 2 and 3, however, 
inverse correlation between tHcy and ADMA 
concentration started to appear in stage 4. 
Interaction between homocysteine and ADMA 
was estimated to occur by metabolic relationship 
between ADMA and transfer methyl reactions. 
ADMA is produced from methylated protein of 
arginin residue. PRMT type 1 utilized AdoMet=S-
adenocylmethionine/SAM as a methyl donor and 
produced AdoHcy=S-adenocylhomocysteine/SAH 
(and ﬁnally homocysteine) as its by product. Since 
ADMA is synthesized from proteolysis of methylated 
protein, the hypothesis was that increased SAM-
dependent protein methylation could result in increased 
ADMA production and increased homocysteine. 
This hypothesis was supported by an experimental 
study using animals (monkeys) supplemented with 
methionine-rich and folate-deﬁcient food, the results of 
which indicated there was elevation of ADMA plasma 
concentration. Methionine-rich and folate-deﬁcient 
food caused three times greater elevation of plasma 
tHcy and ADMA. It also suggested that the higher the 
ADMA concentration, the closer its correlation with 
tHcy; and occurrance vasodilation impairment was 
dependant on the endothelium of the carotid arteries 
of the animals (8). 
In a clinical study, eight hours after supplementing 
standard oral methionine (100 mg/kg), plasma ADMA 
increased from 1.4   0.2 to 2.0   0.2  M (p<0.05), plasma 
tHcy increased from 6.9   1.6 to 28.4   3.5  M (p<0.05), 
and brachial artery vasodilation decreased by 80%. 
Brachial artery vasodilation had inverse correlation 
with plasma ADMA (p<0.05) and has linear correlation 
with L-arginine/ADMA ratio (p<0.01). Similar ﬁndings 
were reported by Stuhlinger et al (8). 
Evidence of the metabolic correlation between 
homocysteine and ADMA was also reported from 
studies with cell culture. Incubation of endothelial 
cells with L-methionine or L-homocysteine produced 
dosage-dependant ADMA elevations on the culture 
media (8). 
Several control studies have reported the 
relationship between hyperhomocysteinemia and 
plasma ADMA elevation in human subjects with 
coronary artery disease, peripheral arterial disease, 
and stroke (8). 
It wasn’t fully understood how ADMA 
increased in hyperhomocysteinemia. Initially, it was 
hypothesized that the conditions that could cause 
homocysteine elevation included methionine-rich 
food, which could elevate SAM intracellular level and 
thus increase ADMA production by supporting SAM-
dependant PRMT activities. However, currently this 
mechanism is considered not likely, since typically 
hyperhomocysteinemia causes elevation of SAH level 
in tissue, but it is not true with the level of SAM . 
Although hyperhomocysteinemia probably does not 
increase PRMT activity with the increase of cellular 
SAM level, however, it is still possible that up regulation 
of PRMT expression occurs in hyperhomocysteinemia 
(8). 
Other possible mechanism of ADMA elevation in 
hyperhomocysteinemia is decreased kidney function 
and decreased DDAH activity- that metabolize ADMA 
to citrulline. Homocysteine is reported to be able to 
inhibit DDAH activity in vitro, perhaps through an 
oxidative reaction with its active site residue (8). 
 eninoihtatsyc-tneicﬁed htiw ecim no yduts a nI
-synthase (CBS) that resulted in high homocysteine, 
there was decreased mRNA concentration from two 
main DDAH enzymes: DDAH-1 and DDAH-2. This 
indicated that homocysteine could regulate DDAH 
expression and activity (8). 
All recent studies on cell cultures in animals and 
human subjects reported that ADMA was metabolically 
associated with homocysteine. This indicated the 
inﬂuence of ADMA elevation on vascular dysfunction 
during hyperhomocystinemia. Homocysteine could 
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increase ADMA by inhibiting DDAH activity or by 
stimulating oxidative stress which in turn wouldl 
inactivate DDAH oxidative. In contrast, homocysteine 
could elevate ADMA by stimulating endoplasmic 
reticulum stress and apoptosis that resulted in elevation 
of protein proteolysis containing methylarginine 
residue. 
Correlation analysis between ADMA and tHcy 
concentration in each CKDseverity level indicated a 
positive correlation in CKD stage 2 and 3, however, 
inverse correlation between tHcy and ADMA 
concentration started to appear in CKD stage 4. 
This can be explained that in situation in which 
homocysteine elevated, SAH intracellular level 
could increase. Since SAH is a potent inhibitor for 
transmethylation reactions, its accumulation can result 
in macromolecules hypomethylation. 
Consistent with this mechanism, 
DNA hypomethylation is observed on 
hyperhomocysteinemic patients with kidney 
problems. It was also observed that ADMA production 
by endothelial cells was inhibited by SAH incubation 
(9). 
Appropriateness of an assay method is very 
important since it affects the correlation power between 
ADMA and homocysteine. In our study, ADMA was 
assayed by ELISA method, in which control precision 
among assays could be obtained (by coefﬁcient of 
variation) by 14% of the control concentration range 
of 0.24 – 0.58, all of which indicated that ADMA is 
closely metabolically associated with homocysteine. 
These evidences indicated a model in which ADMA 
elevation could be an integrating mechanism for 
vascular dysfunction in hyperhomocysteinemia. 
Homocysteine could increase ADMA by inhibiting 
DDAH activity through a direct chemical reaction 
with cysteine active site or by stimulating oxidative 
stress and DDAH oxidative inactivation as the result. 
On the other hand, homocysteine could elevate 
ADMA by stimulating endoplasmic reticulum stress 
and apoptosis that resulted in proteolysis elevation 
of protein containing methylarginine residue. ADMA 
accumulation in endothelial cells could inhibit eNOS 
to cause decreased NO products and endothelial 
dysfunction. Release of eNOS sequence triggered 
by ADMA or other oxidants like peroxinitrite could 
accelerate superoxide production and further 
decreased NO availability (8). 
Result of the correlation analysis between ADMA 
and homocysteine showed no signiﬁcant correlation 
between ADMA and tHcy concentration. This perhaps 
can be explained that in several studies conducted, 
some fundamental questions should yet to be 
answered concerning the pathophysiology of ADMA 
in hyperhomocysteinemia. Although most clinical 
studies have indicated that ADMA plasma increased 
in individuals with hyperhomosisteinemia, some 
of them have indicated that hyperhomosisteinemia 
wasn’t always correlated with signiﬁcant elevation 
of plasma ADMA. Similar differences were noted in 
animal models with hyperhomocysteinemia. There 
was three times greater elevation of plasma ADMA 
in hyperhomocysteinemic monkey, but only slight 
elevation occurred in plasma ADMA of CBS-deﬁcient 
mice with hyperhomocysteinemia.
The correlation analysis between ADMA and 
tHcy concentration in each CKD severity level 
showed positive correlation between them in CKD 
stage 2 and 3, however, inverse correlation between 
tHcy and ADMA concentration started to appear in 
stage 4. This could be explained that in situations in 
which homocysteine increased, intracellular SAH 
level could elevate. Since SAH is a potent inhibitor 
for transmethylation reactions, its accumulation could 
result in macromolecules hypomethylation. According 
to this mechanism, DNA hypomethylation is observed 
in hyperhomocysteinemic patients with end-stage 
kidney disease. Also observed that ADMA production 
by endothelial was inhibited by SAH-mediated 
incubation (9). 
In this study, the assay on ADMA was performed 
by ELISA method, of which the control precision 
between assays (between day coefﬁcient variation) was 
 85.0 – 42.0 fo egnar noitartnecnoc lortnoc rof %41 yb
mol/L and 11% for control concentration range 0.6 – 
1.0  mol/L. This probably affected the test precision 
power that resuledt in error /weakening of correlation 
power between ADMA and homocysteine. 
Teerlink in 2005 in his study reported that Pearson 
coefﬁcient correlation distribution was obtained after 
100 simulation experiments, thus to reveal that by 
increasing CV (coefﬁcient correlation) in ADMA assay 
could result in weakening of the estimation of correlation 
power between ADMA and homocysteine. Teerlink 
emphasized that with a very considerable number of 
study subjects, all those simulation experiments would 
still obtain very signiﬁcant correlation. However, with 
less than 100 study subjects, its correlation would be 
statistically insigniﬁcant (p0.05) in all simulation 
experiments, with r  0.2. In contrast with the crucial 
effect of CV elevation on the ADMA assay, artiﬁcial 
elevation of CV in homocysteine assay up to 10% most 
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likely would not affect the correlation power. 
In this study, there were 20 DM patients and 55 non-
DM patients studied. The correlation analysis found 
higher mean of tHcy and ADMA concentrations, but 
it was insigniﬁcant in the non-DM patients compared 
with than in the DM patients (p = 0.246 and p = 0.322). 
This probably was due to some variables being not 
observed in the study such as duration of diabetes 
and anti-diabetes medication as well as the fact that 
analysis was not carried out on each of the CKD stages 
in DM and non-DM groups. 
If tHcy concentration > 12  mol/L was categorized 
as abnormal and this concentration considered as 
cutoff value for CKD risk, by logistic binary test 
on the variables LFG, age, sex, presence of DM, 
hypertension and dyslipidemia, it was found that 
LFG (estimation) was the most important variable (p 
= 0.000) of homocysteine concentration elevation. This 
can be explained that homocysteine is mainly excreted 
by kidney while ADMA in only 5%, thus LFG is very 
essential part of homocysteine concentration. 
If ADMA concentration > 0.75  mol/L (age 
mean 55 years) was categorized as abnormal (kit 
insert reagent), then from this study it was found 33 
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mol/L and 42 subjects (56%) > 0.75  mol/L. If ADMA 
concentration > 0.75  mol/L was considered cutoff 
value for CVD risk, by logistic binary test on variables 
GFR (estimation), age, sex, the presence of DM, 
hypertension, and dyslipidemia, it was found that sex 
and age were statistically the most important variables 
(p = 0.004 and 0.012) of the elevation of ADMA. 
Analysis on sex in this study showed 32 female 
subjects were with ADMA concentration 0.75  mol/L 
(mean age 55 years) and 8 subjects (25%) with ADMA 
concentration < 0.75  mol/L (mean age 58 years). 
From t test, it was found the age mean for the female 
subjects were with ADMA concentration that elevated 
insigniﬁcantly with the female subjects with non-
elevated ADMA (p=0.092).
Other result of the t test showed that age means for 
male subjects with elevated ADMA were signiﬁcantly 
different in male subjects with non-elevated ADMA 
(p=0,011). This could be explained by several clinical 
studies which have reported convincingly of the 
role of ADMA in the progression of cardiovascular 
disease. In a cohort study on 25 patients with kidney 
failure, ADMA and age were found to be the strongest 
predictor for cardiovcascular events and total mortality, 
even after improvements on traditional and new risk 
factors had been made. Another study with control 
case design indicated that middle-age, non-smoking 
men with ADMA concentration in the highest quartile 
had experienced four times greater risk elevation in 
acute coronary events than other quartile (9). 
Our present study revealed that 24 (75%) of the 
female subjects had ADMA concentration elevation, 
while in the male subjects, ADMA elevation occurred 
in 18 of the male subjects (41.9%). This was probably 
associated with the role of women’s hormone - especially 
estrogen - in suppressing ADMA concentration, in 
this study probably most of the female subjects were 
already in the menopause phase, thus their estrogen 
hormone had decreased and consequently elevated 
ADMA. 
This study revealed that there was an increase in 
homocysteine  and ADMA concentration according 
to CKD severity level. In CKD stage 2 to 4 there was 
a tendency of elevation of the ADMA concentration 
mean, but mean of ADMA concentration was lower in 
stage 5. The positive correlation between homocysteine 
and ADMA concentration was showed by ADMA 
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mol/L, and then decreased in stage 4.  e also found 
out that there was negative correlation between tHcy 
and ADMA concentration that started to appear in 
stage 4. This can be explained that in situations in 
which homocysteine increases, intracellular AH level 
can increase as well (hydrolysis reaction of AH to 
Hcy is reversible). ince AH is a potent inhibitor for 
transmethylation, its accumulation can inhibit ADMA 
production by endothelial cells. 
From these results, we suggest that a cohort 
study with equally distributed population number at 
every stage of CKD and a correlation study between 
hyperhomosisteinemia and ADMA, RMT activity, 
DDAH and O formation than gold standard 
in endothelial dysfunction measurement of ow 
mediated dilatation (FMD) should be conducted. 
This study brings forward the opportunity of ﬁnding 
or utilizing therapy target in hyperhomocysteinemic 
patients due to CKD in order to inhibit the effects of 
ADMA on endothelial dysfunction and progression of 
arteriosclerosis. 
Conclusion
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Correction for Review Article - "Development of Immunopathobiogenesis on SIRS-Sepsis" by A. Guntur Hermawan (IBJ Vol. 1 No. 1 April 2009), on page 38. Figure3. Basic Concept of Sepsis (adpated from Guntur, 2000). We regret the error.
